Resmed (RMD) EBITDA (2009 - 2026)

Resmed (RMD) has 18 years of EBITDA data on file, last reported at $499.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 17.25% year-over-year to $499.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 17.4% YoY), and the FY2025 full-year result was $1.8 billion, up 27.57% from the prior year.
• EBITDA for Q1 2026 stood at $499.8 million, up from $491.7 million in the prior quarter.
• Across five years, EBITDA topped out at $499.8 million in Q1 2026 and bottomed at $234.3 million in Q1 2022.
• The 5-year median for EBITDA is $374.6 million (2024), against an average of $356.8 million.
• The widest annual swing landed in 2023, when EBITDA dropped 1.82%; it then jumped 51.67% in 2024.
• A 5-year view of EBITDA shows it stood at $280.2 million in 2022, then dropped by 1.82% to $275.1 million in 2023, then surged by 51.67% to $417.2 million in 2024, then advanced by 17.84% to $491.7 million in 2025, then gained by 1.66% to $499.8 million in 2026.
• The last three EBITDA figures came in at $499.8 million (Q1 2026), $491.7 million (Q4 2025), and $446.5 million (Q3 2025), per Business Quant data.

Peer Comparison